Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
74 hedge funds and large institutions have $18.6M invested in Accelerate Diagnostics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 25 reducing their positions, and 40 closing their positions.
30% less funds holding
Funds holding: 106 → 74 (-32)
44% less capital invested
Capital invested by funds: $33.5M → $18.6M (-$14.9M)
56% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 25
75% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 40
96% less call options, than puts
Call options by funds: $34K | Put options by funds: $842K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$2.19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$870K |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$223K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.54M |
| 2 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$1.51M |
| 3 |
Axa
Paris,
France
|
-$1.32M |
| 4 |
State Street
Boston,
Massachusetts
|
-$873K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$541K |
AXDX Hedge Fund Activity: Q2 2022 in Review
74 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2022, worth a combined $18.6M — down 44% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of AXDX and 10 opened new positions — a net loss of 30 holders — while 25 trimmed existing stakes and 11 added.
The largest buyer was Griffin Asset Management, adding an estimated $2.19M. The largest seller was BlackRock, cutting an estimated $1.54M.
- 74 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2022, down from 106 in Q1 2022.
- Funds reported $18.6M of Accelerate Diagnostics stock for Q2 2022, down 44% quarter-over-quarter.
- 10 funds opened new Accelerate Diagnostics positions in Q2 2022 and 40 closed out, a net change of -30 holders.
- The largest Accelerate Diagnostics buyer in Q2 2022 was Griffin Asset Management, an estimated $2.19M added.
- The largest Accelerate Diagnostics seller in Q2 2022 was BlackRock, an estimated $1.54M sold.
Based on aggregated 13F filings for Q2 2022.